SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron Corp.
GERN 1.370-2.1%Dec 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: louis mason who wrote (522)8/21/1997 6:37:00 PM
From: seminole   of 3576
 
Louis

I believe that the screening for an anti-telomerase compound
must be done in cell culture with cancer cells to be useful.
An inhibitor to the enzyme that can't pass into the cell is
useless. This makes the demands on the inhibitor much more difficult.
In addtion, the inhibitor must not adversely alter other cellular
enzymes or it may harm healthy cells. I think a drug is a long
way off. If anti-telomerase trails are less then a year away,
where are the mice (xenograft) studies? Any referances?

richard
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News